Skip to main content

Table 2 Univariate and multivariate analyses for overall survival in patients with multiple myeloma obtained from the GSE24080 and GSE9782 datasets

From: Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myeloma

Variables Univariate analysis Multivariable analysis
HR 95% CI P value HR 95% CI P value
Training set GSE24080
20-gene risk model (high/low) 4.337 3.206–5.868 1.83e−21* 3.532 2.625–4.87 1.38e−14*
Age (y) 1.024 1.007–1.041 5.21e−03* 1.009 0.992–1.026 0.315
Sex (male/female) 0.971 0.716–1.317 0.850
IgA_Isotype (Y/N) 1.093 0.777–1.537 0.609
Serum β2MG ≥ 3.5 mg/L (Y/N) 2.211 1.633–2.994 2.92e−07* 1.548 1.034–2.32 0.034*
CRP ≥ 8.0 mg/L (Y/N) 1.485 1.096–2.011 0.011* 1.14 0.822–1.58 0.433
sCr ≥ 2.0 mg/L (Y/N) 2.746 1.866–4.039 2.93e−07* 1.442 0.929–2.237 0.102
LDH > upper limit of normal (> 190 U/L) (Y/N) 2.32 1.716–3.137 4.57e−08* 1.502 1.078–2.093 0.016*
Serum ALB < 3.5 g/L (Y/N) 1.927 1.329–2.794 5.41e−04* 1.255 0.835–1.886 0.274
Hemoglobin < 100 g/L (Y/N) 1.625 1.191–2.216 2.17e−03* 0.982 0.693–1.391 0.916
Bone marrow plasma cells (%) 1.01 1.004–1.016 9.14e−04* 1 0.993–1.007 0.952
Validation set GSE9782
20-gene risk model (high/low) 2.737 2.11–3.55 3.33e−14* 3.017 2.162–4.211 8.35e−11*
Serum β2M ≥ 3.5 mg/L (Y/N) 1.961 1.315–2.924 9.6e−04* 1.686 1.098–2.588 0.017*
CRP ≥ 8.0 mg/L (Y/N) 2.107 1.416–3.135 2.36e−04* 1.6 1.057–2.423 0.026*
Serum ALB < 3.5 g/L (Y/N) 1.798 1.298–2.49 4.17e−04* 1.618 1.058–2.476 0.026*
  1. HR hazard ratio, 95%CI 95% confidence interval, β2MG β2-microglobulin, CRP C-reactive protein, sCr serum creatinine, LDH lactate dehydrogenase, ALB albumin; *, statistically significant